Compare Ascendis Pharma A/S (ASND) vs Equinor ASA (EQNR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Equinor ASA — how do they compare? Ascendis Pharma A/S trades at $256.37 (market cap $16.67B), while Equinor ASA trades at $40.85 (market cap $97.58B). The key difference: Equinor ASA is far larger — about 5.9× Ascendis Pharma A/S's market cap, and Equinor ASA pays a 3.81% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | EQNR | |
|---|---|---|
Market Cap | $16.67B | $97.58B |
Sector | Health | Energy |
52-Week High | $277.18 | $42.40 |
52-Week Low | $189.74 | $22.41 |
Enterprise Value | $17.04B | $106.28B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
Equinor (EQNR) trades at $40.865, down 0.3% on the day, with a bullish technical signal from moving averages. The company reported mixed Q2 2026 earnings, missing EPS estimates but showing strong revenue growth of 40% year-over-year. Valuation ratios remain attractive with a P/E of 11.09 and EV/EBITDA of 2.3. Recent news highlights a 22.2% monthly rally, driven by higher energy prices and output, alongside ongoing share buybacks and consistent dividend payments.
The outlook is cautiously positive, supported by robust cash flow and strategic investments in production growth. However, risks include volatile energy prices, execution challenges in portfolio adjustments, and a high tax burden impacting net margins. Analyst sentiment is mixed, with 30% buy ratings but majority holds, reflecting valuation concerns after recent gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →
